Understanding muscle pathology reports is important to best treat rheumatology patients. Peter Pytel, MD, shared pearls of wisdom specific to the autoimmune inflammatory myopathies and gave a detailed review of what rheumatologists need to know, during the 2022 ACR Education Exchange.
The Presentation A pale, quiet woman—her mother—wheeled the girl into my clinic. It was a blistering Florida day, and the girl was shivering. She glanced up at me when I said hello and asked her name. “Hi,” she said, giving me a broad smile. Her smile was the only broad thing about her. Her elbows…
Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…
A reader offers more diagnostic tools for inflammatory myopathies
Without a single set of diagnostic criteria for identifying polymyositis, dermatomyositis, or myositis and scant evidence-based therapeutic guidelines, these rare muscle diseases can be hard to manage
Career marked by the quest to define the antigenic targets of autoimmunity in people with systemic lupus erythematosus (SLE), inflammatory myopathies, polymyositis, and dermatomyositis
Treatment options and recent research for juvenile dermatomyositis.
Advances in diagnostic modalities and treatments emerge